Summary & Overview
HCPCS J0217: Injection, velmanase alfa-tycv, 1 mg
HCPCS Level II code J0217 denotes the injection of velmanase alfa-tycv, measured per 1 mg. This code identifies administration of a recombinant enzyme replacement therapy used in outpatient infusion settings and plays a role in claims processing, benefit design, and access to specialty biologic treatments nationwide. Its use matters for hospital outpatient departments, infusion centers, and payer medical policies that govern coverage for high-cost biologics.
Key payers in this national overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of what J0217 represents clinically and operationally, the typical sites of service, and which payers commonly adjudicate claims for this type of injectable biologic. The publication also outlines common areas of payer policy attention—coverage criteria, site-of-care considerations, and billing accuracy—and highlights the benchmarks and contextual policy developments that affect billing and reimbursement for enzyme replacement therapies.
This summary equips billing managers, revenue cycle leaders, and clinical administrators with the essential context needed to identify where J0217 fits in the service line, how national payers approach coverage, and what topical issues to monitor when managing claims and approvals for velmanase alfa-tycv injections.
Billing Code Overview
HCPCS Level II code J0217 represents an injection of velmanase alfa-tycv, dosed per 1 mg. This code describes a biologic enzyme replacement therapy formulation supplied as an injectable medication.
Service type: injectable biologic therapy administration
Typical site of service: infusion center or outpatient hospital clinic
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 6-year-old child with a confirmed diagnosis of alpha-mannosidosis presents to an infusion center for enzyme replacement therapy with velmanase alfa. The patient arrives with a parent, is checked in at outpatient infusion services, and undergoes a brief nursing assessment including vital signs and verification of allergy history and medication list. An infusion nurse prepares the dose of J0217 (velmanase alfa-tycv, 1 mg) per weight-based dosing ordered by the treating metabolic specialist. The medication is administered intravenously over the recommended infusion time under continuous monitoring for infusion-related reactions. The workflow includes pre-medication orders (antipyretic/antihistamine/steroid) if prior reactions occurred, documentation of lot number and amount administered, and observation for 30–60 minutes post-infusion. Billing uses HCPCS Level II code J0217 with applicable modifiers to indicate billing nuances (for example, billing for multiple vials, unusual circumstances, or attended by a specialized provider). Typical sites of service include outpatient hospital infusion centers, freestanding infusion clinics, and specialty ambulatory care centers. Typical patient scenario: pediatric or adult patients with inherited alpha-mannosidosis receiving chronic, recurring intravenous infusions of velmanase alfa as enzyme replacement therapy, scheduled every 1–2 weeks per the prescribing protocol.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|